Gene-Guided drug cocktail shows promise for Tough-to-Treat gynaecological cancers
NCT ID NCT04065269
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a new drug (ceralasertib) alone or combined with either olaparib or durvalumab in 174 people whose gynaecological cancer has returned. The study groups patients by their cancer type and whether they have a change in the ARID1A gene. The goal is to see if these combinations can shrink tumors or stop them from growing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Imperial College NHS Trust
London, United Kingdom
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Royal United Hospital
Bath, BA1 3NG, United Kingdom
-
The Beatson
Glasgow, United Kingdom
-
The Christie
Manchester, United Kingdom
-
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, K1H 8L6, Canada
-
The Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
University of Montreal Hospital Centre
Montreal, Quebec, H2X 3E4, Canada
-
Western General Hospital
Edinburgh, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can adding radiation boost the power of immunotherapy in advanced cervical cancer?
- Can a Two-Drug combo tame a rare and aggressive gynecologic cancer?
- Digital therapy aims to tame the fear that haunts cancer survivors
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Timing matters: early platelet booster may prevent dangerous drops in cervical cancer treatment
- Vaginal fluid may hold key to early cancer detection